Abstracts tagged "Psoriatic arthritis"

Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Alan Kivitz¹, Elena Tomaselli Muensterman², Arthur Kavanaugh³, Désirée van der Heijde⁴, Piotr A. Klimiuk⁵, Guillermo Valenzuela⁶, Eva Dokoupilova⁷, Gabrielle Poirier⁸, Bhaskar Srivastava⁸, Sue Dasen⁸, Xinyan Zhang⁸, Mona Trivedi², Haoling Holly Weng⁹, Ting Hong¹⁰, Peter Pothula¹⁰ and Xenofon Baraliakos¹¹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Division of Rheumatology, Allergy & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University and MEDICAL PLUS, s.r.o., Brno and Uherské Hradiště, Czech Republic, ⁸Nimbus Discovery, Inc., Boston, MA, ⁹HW MedAdvice LLC, San Diego, CA, ¹⁰Takeda Development Center Americas, Inc., Boston, MA, ¹¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…
Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni¹, Philip J. Mease², Joseph Merola³, Frank Behrens⁴, Ennio G Favalli⁵, Dennis McGonagle⁶, William R Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Jason Coarse¹¹ and Laure Gossec¹², ¹Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁵ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁶Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁷Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Irigny, France, ¹¹UCB Pharma, Morrisville, NC, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…
Abstract Number: 1044 • ACR Convergence 2023
Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts
Ari Polachek¹, Victoria Furer², Sydney Thib³, Liran Mendel², Ori Elkayam² and Lihi Eder⁴, ¹Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) can manifest with different musculoskeletal (MSK) features. Ultrasound (US) optimizes the assessment of the different MSK features in PsA. However, there…
Abstract Number: 1418 • ACR Convergence 2023
Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Alice B. Gottlieb¹, April W. Armstrong², Joseph Merola³, Andrew Napoli⁴, Miroslawa Nowak⁴, Subhashis Banerjee⁴, Thomas Lehman⁵ and Philip J. Mease⁶, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Keck School of Medicine of University of Southern California, Los Angeles, CA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Philadelphia, PA, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines involved in plaque psoriasis (PsO) and PsA pathophysiology. Deucravacitinib is a first-in-class, oral, selective, allosteric…
Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Andrew Östör¹, Filip Van den Bosch², Kim A Papp³, Cecilia Asnal⁴, Ricardo Blanco⁵, Jacob Aelion⁶, Vassilis Stakias⁷, Thomas Iyile⁷, Kyle Carter⁷, Ahmed Soliman⁷, Leonidas Drogaris⁷, Michael Chen⁷, Byron Padilla⁷ and Alan Kivitz⁸, ¹Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶West Tennessee Research Institute, Jackson, TN, ⁷AbbVie, Inc., North Chicago, IL, ⁸Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…
Abstract Number: 1688 • ACR Convergence 2023
Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
Philip J. Mease¹, Peter C. Taylor², Kurt de Vlam³, Paul M. Peloso⁴, Apinya Lertratanakul⁵, Dieter Wetzel⁶, Nikolai Brun⁷, Brian Wiens⁸, Jan Brandt-Juergens⁹, Edit Drescher¹⁰, Eva Dokoupilova¹¹, Anna Rowińska-Osuch¹², Nadia Abdel-Kader Martin¹³ and Frank Behrens¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴ACELYRIN, INC., Naples, FL, ⁵ACELYRIN, Chicago, IL, ⁶toclinco GmbH, Freiburg im Breisgau, Germany, ⁷Affibody AB, Solna, Sweden, ⁸ACELYRIN, Inc., Half Moon Bay, CA, ⁹rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰Csolnoky Ferenc Hospital / Vital Medical Center Private Clinci, Veszprém, Hungary, ¹¹Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ¹²ETG Warszawa, Warsaw, Poland, ¹³Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany
Background/Purpose: IL-17 inhibition demonstrates efficacy in multiple disease domains in psoriatic arthritis. Izokibep is a unique IL-17A inhibitor with high IL-17A binding affinity (KD= 0.3…
Abstract Number: 2077 • ACR Convergence 2023
A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Elaine Bell¹, Marinella Calle² and Iain McInnes³, ¹Medscape Global Education, London, United Kingdom, ²MEDSCAPE GLOBAL, London, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…
Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Aisha Vadhariya¹, Sarah Ross¹, Brenna Brady², Helen Varker², Anh Thu Tran² and Jessica A Walsh³, ¹Eli Lilly and Company, Indianapolis, IN, ²Merative, Cambridge, MA, ³Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…
Abstract Number: 2438 • ACR Convergence 2023
Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
Órla Tynan¹, Mary Canavan², Achilleas Floudas³, Conor Smith⁴, Aoife O' Rourke⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ³Dublin City University, Dublin, Ireland, ⁴Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Synovial fibroblasts (FLS) are key contributors to joint inflammation and damage in patients with Rheumatoid (RA) and Psoriatic Arthritis (PsA). Recent studies have identified…
Abstract Number: 0352 • ACR Convergence 2023
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: 0495 • ACR Convergence 2023
Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
Jesus Sanz¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez -Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez-Pampin⁷, Manuel Barreiro de Acosta⁸, Antonio Aznar Esquivel⁹, Marta Carrillo Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², Lourdes Ladehesa Pineda¹³, Eva Iglesias Flores¹⁴, carolina Merino¹⁵, Yago gonzalez-Lama¹⁶, Marta Arévalo Salaet¹⁷, Xavier calvet¹⁸, Anahy Maria Brandy-Garcia¹⁹, Marta Izquierdo Romero²⁰, SARA MANRIQUE²¹, Raúl Olmedo²², Jose Francisco Garcia Llorente²³, Sandra Pérez²⁴, Inmaculada Ros²⁵, Nuria Rull²⁶, Jose Antonio Pinto Tasende²⁷, Patricia Ucha Abal²⁸, Carlos M González²⁹, Fernando José Rodríguez Martínez³⁰, Soledad Serrano Ladron de Guevara³¹, Marta Domínguez³², Francisco Javier Prado³³, Enrique González-Dávila³⁴ and Ana Gutierrez-Casbas³⁵, ¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Public Health System, Madrid, Spain, ⁷Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁸Gastroenterology department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁹Rheumatology Department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Gastroenterology department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Gastroenterology department Basurto Hospital, Bilbao, Spain, ¹³Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ¹⁴Gastroenterology department Hospital Reina Sofia, Cordoba, Spain, ¹⁵Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁶Gastroenterology department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹⁷Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ¹⁸Gastroenterology department University Hospital Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Gastroenterology department Hospital Cabueñes, Gijon, Spain, ²¹Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ²²Gastroenterology department Hospital Regional Universitario Málaga, Malaga, Spain, ²³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ²⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ²⁵Rheumatology Department HUSLL, Palma de Mallorca, Spain, ²⁶Gastroenterology department HUSLL, Palma de Mallorca, Spain, ²⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁸Gastroenterology department Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ²⁹Rheumatology Department Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³⁰Rheumatology Department Hospital Universitario General Santa Lucia, Murcia, Spain, ³¹Gastroenterology department Hospital Universitario General Santa Lucia, Murcia, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ³⁴Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ³⁵Gastroenterology department Hospital General Universitario de. Dr. Balmis de Alicante Servicio Digestivo. ISABIAL y CIBERehd, Alicante, Spain
Background/Purpose: EISER is a cross-sectional, multicenter, observational, SER-GETECCU cooperative study involving 13 Spanish hospitals whose main objective was to estimate the prevalence of undiagnosed Inflammatory…
Abstract Number: 0541 • ACR Convergence 2023
Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
Irini Flouri¹, Nestor Avgoustidis², Anastasios Eskitzis², Argyro Repa², Katerina Pateromichelaki², Sofia Pitsigavdaki³, Myrto Nikoloudaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…
Abstract Number: 1051 • ACR Convergence 2023
Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis
sibel aydin¹, seyyid acikgoz², Ummugulsum Oguz³, antonio Vieira⁴, patrick Leclerc⁴, Suharsh Shah⁴, Lihi Eder⁵ and Gurjit S Kaeley⁶, ¹University of Ottawa - Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, ⁵Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being shown repeatedly, several barriers persist and stand in the way of…
Abstract Number: 1419 • ACR Convergence 2023
Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
Peter Nash¹, Iain McInnes², Christopher T. Ritchlin³, Lai-Shan Tam⁴, Enrique Soriano⁵, Michael Starr⁶, Emmanouil Rampakakis⁷, Frederic Lavie⁸, May Shawi⁹, Xenofon Baraliakos¹⁰ and Philip J. Mease¹¹, ¹School of Medicine, Griffith University, Brisbane, Australia, ²University of Glasgow, Glasgow, United Kingdom, ³University of Rochester Medical Center, Department of Medicine – Allergy/Immunology and Rheumatology, Rochester, NY, ⁴The Chinese University of Hong Kong, New Territories, China, ⁵Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Division of Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁷McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹Immunology, Janssen Research & Development, LLC, Titusville, NJ, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Pain in PsA has multifaceted origins (e.g., peripheral joint inflammation, axial involvement [axPsA], skin lesions, dactylitis, enthesitis, underlying conditions) and can be difficult to…
Abstract Number: 1435 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
Lars Erik¹, Mauro Keiserman², Kim A Papp³, Leslie McCasland⁴, Douglas White⁵, Vassilis Stakias⁶, Thomas Iyile⁶, Kyle Carter⁶, Ahmed Soliman⁶, Leonidas Drogaris⁶, Michael Chen⁶, Byron Padilla⁶ and Frank Behrens⁷, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Pontifical Catholic University School of Medicine, Porto Alegre, Brazil, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Arthritis and Rheumatism Associates, Jonesboro, AR, ⁵Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ⁶AbbVie, Inc., North Chicago, IL, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody that inhibits interleukin-23 by targeting its p19 subunit with high affinity and specificity, is approved for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].